GlassScriptPhysician profile
Muhammad Zaman
NPI 1477806339
$37,390.38
in general payments reported to CMS, 2019-2025
19 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.57 · 2021: $279 · 2022: $2,409 · 2023: $749 · 2024: $19K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $20K · Travel and Lodging: $7,523 · Food and Beverage: $5,648 · Education: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $20,416.67 |
| Travel and Lodging | $7,523.22 |
| Food and Beverage | $5,647.71 |
| Education | $1,055.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16,012.66 | 2021-2025 | Assurity, Ensite, Ensite Precision |
| Medtronic, INC. | $8,406.54 | 2022-2025 | Micra, Azure Xt Dr Mri Surescan, Onyx Frontier |
| Boston Scientific Corporation | $7,457.51 | 2022-2025 | Farapulse |
| Biosense Webster, INC. | $2,560.47 | 2025 | Carto 3 |
| Biotronik INC. | $1,384.58 | 2020-2025 | Amvia Edge, Pamira, Acticor 7 Vr-T Dx |
| Philips North America LLC | $391.22 | 2025 | Igt Devices Undivided |
| Astrazeneca Pharmaceuticals LP | $260.24 | 2022-2023 | Farxiga |
| Medical Device Business Services, INC. | $238.70 | 2023 | Carto 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.65 | 2021-2024 | Lifevest |
| Cvrx, INC. | $137.55 | 2022 | |
| Terumo Medical Corporation | $133.30 | 2022-2023 | Glidewire |
| Angiodynamics, INC. | $58.53 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.91 | 2023 | Opsumit, Uptravi |
| Teleflex LLC | $22.73 | 2023 | Turnpike |
| Pfizer INC. | $20.83 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.82 | 2023 | Camzyos |
| Chiesi USA, INC. | $18.69 | 2021 | |
| Amgen INC. | $15.40 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Zaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.